OOIR: Observatory of International Research

Papers

(The H4-Index of npj Breast Cancer is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor	228
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer	154
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer	137
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab	136
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases	127
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer	93
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape	78
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer	77
TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression	71
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer	64
Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses	62
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ	58
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer	53
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy	50
Reversion of breast epithelial polarity alterations caused by obesity	49
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade	49
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study	48
Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation	47
Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning	45
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer	42
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer	41
International survey on invasive lobular breast cancer identifies priority research questions	40
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer	38
Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors	38
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer	37

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial	35
Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients	35
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation	35
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer	34
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer	33
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women	32
Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families	32
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function	32